In a major boost to India’s COVID 19 vaccination drive, the Drugs Controller General of India on Tuesday granted emergency use authorization to 3 vaccines – Bharat Biotech’s Covaxin, Zydus Cadila’s ZyCoV – D and Biological E Limited’s Corbevax for children between the age of 6-12, 5-12, 12 years above respectively.
“If children are safe, the country is safe. It makes me really happy to announce that from March 16, children in (the) 12-14 age group can get vaccinated against Covid,” health minister Mansukh Mandaviya had tweeted, announcing the government’s decision to extend COVID-19 vaccination for 12-13 years and 13-14 years.
Covaxin (6-12 years old children)
The DCGI has directed Bharat Biotech to submit the safety data, including the data on the severe events with due analysis every 15 days for the first 2 months.
#COVID19 | DCGI grants emergency use authorisation to ZycovD (Zydus Cadila vaccine) for children above the age of 12 years: Sources
Advertisement— ANI (@ANI) April 26, 2022
ZyCoV-D (12 years+ old children)
The world’s first DNA-plasmid-based vaccine ZyCoV-D has been green signalled for emergency-use authorisation from the DCGI for use in adolescents 12 years old and above. DNA-Plasmid-based ZyCoV-D will be a three-dose vaccine and is to be administered intradermally through a needle-free injection system (NFIS).
#COVID19 | DCGI also grants emergency use authorisation to ZycovD (Zydus Cadila vaccine) for children above the age of 12 years for a two-dose regimen: Sources
— ANI (@ANI) April 26, 2022
Advertisement
Corbevax (5-12 years old children)
Corbevax is India’s first indigenously developed Receptor Binding Domain (RBD) Protein sub-unit vaccine against COVID-19. The DCGI had earlier approved Corbevax for restricted use in an emergency situation in adults on December 28.
#COVID19 | DCGI (Drugs Controller General of India) grants emergency use authorisation to Corbevax for children between the age of 5-12 years: Sources
Advertisement— ANI (@ANI) April 26, 2022
For more breaking news, click here.